Trial Search Results

Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

The aim of the study is to see if there any changes in the quality of life for patients that are undergoing radical prostatectomy.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


Inclusion Criteria:Patients diagnosed with liver cancer based on biopsy or serum AFP level,
associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or

   - Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or
   nodular hyperplasia.

   - Patients with hepatitis B or hepatitis C viral infections not associated with liver
   cancer. Exclusion Criteria:Patients will be excluded if, upon looking through their
   medical records, information required for data analysis are missing.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mei-Sze Chua